In vivo comparative antithrombotic effects of ioxaglate and iohexol and interaction with the platelet antiaggregant clopidogrel

Investigative Radiology

Volumn 38, Issue 1, 2003, Pages 34-43

  Labarthe, Benoit ^a   Idee, Jean Marc ^b,c   Burnett, Roger ^a   Corot, Claire ^a  

^a Research Division   (France)

^b Phatology Department   (France)

^c Research Division   (France)

Author keywords

Clopidogrel; Contrast media; Ferric chloride; Iohexol; Ioxaglate; Platelets; Thrombosis

Indexed keywords

CLOPIDOGREL; FERRIC CHLORIDE; HEPARIN; IOHEXOL; MEGLUMINE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; SODIUM CHLORIDE; VISIPAQUE 320;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY THROMBOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOPPLER FLOWMETER; DRUG ACTIVITY; DRUG POTENTIATION; FILTER; IN VIVO STUDY; MALE; NONHUMAN; OCCLUSION; PAPER; PRIORITY JOURNAL; RAT; THROMBOCYTE; THROMBUS; TIME; WEIGHT;

EID: 12244294471     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200301000-00005     Document Type: Article

References (43)

1. Meade TW. Hypercoagulability and ischemic heart disease. Blood Rev 1987;1:2-8.
2. Cutlip DE. Stent thrombosis: historical perspectives and current trends. J Thromb Thrombolysis 2000;10:89-101.
3. Inoue T, Sohma R, Miyazaki T, et al. Comparison of activation process of platelets after coronary stem implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000;86:1057-1062.
4. Bates ER. Ischemic complications after percutaneous transluminal coronary angioplasty. Am J Med 2000;108:309-316.
5. Eloy R, Corot C, Belleville J. Contrast media for angiography: Physicochemical properties, pharmacokinetics and biocompatibility. Clin Mat 1991;7:89-197.
6. Idée JM, Corot C. Thrombotic risk associated with the use of iodinated contrast media in interventional cardiology: pathophysiology and clinical aspects. Fundam Clin Pharmacol 1999;13:613-623.
7. Chronos NAF, Goodall AH, Wilson DJ, et al. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation 1993;88:2035-2044.
8. Heptinstall S, White A, Edwards N, et al. Differential effects of three radiographic contrast media on platelet aggregation and degranulation: implications for clinical practice? Br J Haematol 1998;103:1023-1030.
9. Li X, Gabriel DA. Differences between contrast media in the inhibition of platelet activation by specific platelet agonists. Acad Radiol 1997;4:108-114.
10. Husted SE, Kanstrup H. Thrombotic complications in coronary angioplasty. Ionic versus nonionic low-osmolar contrast media. Acta Radiol 1998;39:340-343.
11. Schräder R. Thrombogenic potential of nonionic contrast media: fact or fiction? Eur J Radiol 1996;23(Suppl 1):S10-S13.
12. d'Anglemont de Tassigny A, Idée JM, et al. Comparative effects of ionic and nonionic iodinated low-osmolar contrast media on platelet function with the PFA-100 (platelet function analyser). Invest Radiol 2001;36:276-282.
13. Heptinstall S, Patterson C, Snaderson H, et al. Meglumine, a component of preparations of the radiographic contrast medium ioxaglate, inhibits platelet aggregation. Haemostasis 2000;30:57.
14. Parvez Z, Moncada R, Fareed J, et al. Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures. Invest Radiol 1984;19:208-211.
15. Mehta SR, Yusuf S, Peters RJ, et al. Effect of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
16. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990;60:269-280.
17. Lockyer S, Kambayashi JI. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. J Cardiovasc Pharmacol 1999;33:718-725.
18. Milliken GA. Analysis of repeated measures design. In: Berry DA, ed. Statistical methodology in the pharmaceutical sciences. New York, NY: Dekker; 1990;83-116.
19. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by apoA1 Milano. Arterioscler Thromb Vasc Biol 1999;19:378-383.
20. Falk E, Fuster V, Shah PK. Interrelationship between atherosclerosis and thrombosis. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis. Philadelphia, PA: Lippincott-Raven; 1998;45-58.
21. Corot C, Stucker O, Duverger JP, et al. Effects of iodinated contrast agents on the formation of platelet thrombi in rat arterioles. Invest Radiol 1994;29(Suppl 2):S203-S205.
22. Aguejouf O, Malfatti E, Doutremepuich F, et al. Thrombogenic potential of contrast media in an experimental model of laser-induced thrombosis. Thromb Res 2000;100:167-177.
23. Levi M, Biemond BJ, Sturk A, et al. Variable effects of radiological contrast media on thrombus growth in a rabbit jugular vein thrombosis model. Thromb Haemost 1991;66:218-221.
24. Heran C, Morgan S, Kasiewski C, et al. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur J Pharmacol 2000;389:201-207.
25. Bernat A, Mares AM, Defreyn G, et al. Effect of various antiplatelet agents on acute arterial thrombosis in the rat. Thromb Haemost 1993;70:812-816.
26. Umemura K, Ishihara H, Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 1995;80:209-216.
27. Zhu Y, Tomasiak R, Fay WP. Do clinically-relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis? Thromb Res 2002;105:413-418.
28. Idée JM, Lancelot E, Berthommier C, et al. Effects of nonionic monomeric and dimeric iodinated contrast media on renal and systemic haemodynamics in rats. Fundam Clin Pharmacol 2000;14:11-18.
29. Deray G, Bagnis C, Jacquiaud C, et al. Renal effects of low and iso-osmolar contrast media on renal hemodynamics in a normal and ischemic dog kidney. Invest Radiol 1999;34:1-4.
30. Karstoft J, Baath L, Jansen I, et al. Vasoconstriction of isolated arteries induced by angiographic contrast media. A comparison of ionic and nonionic contrast media iso-osmolar with plasma. Acta Radiol 1995:36:312-316.
31. Limbruno U, Petronio AS, Amoroso G, et al. The impact of coronary artery disease on the coronary vasomotor response to nonionic contrast media. Circulation 2000;101:491-497.
32. Baumgart D, Haude M, George G, et al. High-volume non-ionic dimeric contrast medium: first experiences during complex coronary interventions. Cath Cardiovasc Diagn 1997;40:241-246.
33. Roussi J, Berge N, Bonneau M, et al. Differential effects of ioxaglate and iodixanol in an in vivo and an ex vivo models of arterial thrombosis in the pig. Fundam Clin Pharmacol 2000;14:285(abstract).
34. Grines CL, Mickelson JK, Diaz C, et al. Acute thrombosis in a canine model of arterial injury: effect of ionic versus nonionic contrast media. J Invas Cardiol 1991;3:18B-23B.
35. Markou CP, Chronos NAF, Hanson SR. Antithrombotic effects of ionic and non-ionic contrast media in nonhuman primates. Thromb Haemost 2001;85:488-493.
36. Harjai KJ, Grines C, Stone GW, et al. Frequency, determinants and clinical implications of intracoronary thrombus following primary angioplasty for acute myocardial Infarction. J Am Coll Cardiol 2002;39(suppl 5):49.
37. Cucherat M, Leizorovicz A. Effects of non-ionic contrast media on abrupt vessel closure and ischemic complications after angioplasty. A meta-analysis. Am J Cardiol 1999;84(suppl):98P.
38. Fay WP, Parker AC. Effects of radiographic contrast agents on thrombin formation and activity. Thromb Haemost 1998;80:266-272.
39. Al Dieri R, De Muinck E, Hemker HC, et al. An ionic contrast agent inhibits platelet-dependent thrombin generation and boosts the effect of abciximab. Thromb Haemost 2001;85:944-945.
40. Valenti R, Motta A, Merlini S, et al. Iopiperidol: non-ionic iodinated contrast medium with promising anticoagulant and antiplatelet properties. Acad Radiol 1999;6:426-432.
41. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.
42. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-317.
43. Savi P, Labouret C, Delesque N, et al. P2Y (12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-383.